PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 2 months ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 2 months ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 1 year 3 months ago Sanofi augmente sa participation dans Innate Pharma Capital Actions Franchissement De Seuils Sanofi Innate Pharma
BRIEF published on 05/02/2025 at 15:27, 1 year 3 months ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
PRESS RELEASE published on 05/02/2025 at 15:22, 1 year 3 months ago Franchissement de seuils Déclaration de franchissement de seuils par Sanofi pour Innate Pharma via augmentation de capital Augmentation De Capital Franchissement De Seuils Sanofi Innate Pharma
BRIEF published on 04/29/2025 at 21:05, 1 year 3 months ago Innate Pharma Presents Promising Preclinical Data for IPH4502 at AACR 2025 Preclinical Data Innate Pharma IPH4502 Nectin-4 Antibody Drug Conjugate
BRIEF published on 04/29/2025 at 21:05, 1 year 3 months ago Innate Pharma présente des données précliniques prometteuses pour IPH4502 à l'AACR 2025 Innate Pharma Données Précliniques Conjugué Anticorps-médicament IPH4502 Nectine-4
PRESS RELEASE published on 04/29/2025 at 21:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma presents preclinical data for IPH4502, a Nectin-4 targeting ADC, showing superior anti-tumor efficacy in multiple cancer models at AACR 2025 Annual Meeting Preclinical Data Innate Pharma IPH4502 AACR 2025 Nectin-4 ADC
PRESS RELEASE published on 04/29/2025 at 21:00, 1 year 3 months ago Informations privilégiées / Autres communiqués Innate Pharma présente les données précliniques prometteuses d'IPH4502, un conjugué anticorps-médicament innovant ciblant Nectine-4, au congrès annuel de l'AACR 2025 Préclinique Innate Pharma Conjugué Anticorps-médicament IPH4502 AACR 2025
BRIEF published on 04/24/2025 at 07:40, 1 year 3 months ago Innate Pharma Secures €15M Sanofi Investment Capital Increase Innate Pharma Sanofi Investment BCMA ANKET Biotech Partnership
Published on 08/11/2026 at 07:00, 3 hours 43 minutes ago Alaska Energy Metals Announces Closing of Shares for Debt Settlement
Published on 08/11/2026 at 00:40, 10 hours 3 minutes ago CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 10 hours 18 minutes ago Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 11 hours 8 minutes ago NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 11 hours 13 minutes ago Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/11/2026 at 10:35, 8 minutes ago Lifefit launches and appoints Neymar Jr. as global brand ambassador
Published on 08/11/2026 at 10:05, 38 minutes ago The Ellinikon Sports Park Opens to All as Europe's Largest Urban Regeneration Project Accelerates Toward Completion
Published on 08/11/2026 at 10:00, 43 minutes ago Rising heat, growing exposure, changing hazards: benign first half of 2026 masks rising natural catastrophe risk, finds Swiss Re Institute
Published on 08/11/2026 at 09:20, 1 hour 23 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 08/10/2026 at 18:00, 16 hours 43 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 16 hours 43 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 16 hours 58 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 22 hours 49 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
